1. Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. (February 2017) Authors: Tolaney, S.; Savulsky, C.; Aktan, G.; Xing, D.; Almonte, A.; Karantza, V.; Diab, S. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Patients' quality of life and side effect perceptions in monarchE, a study of abemaciclib plus endocrine therapy in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer. (April 2021) Authors: Tolaney, S.; Blancas, I.; Im, Y.-H.; Rastogi, P.; Brown, J.; Shahir, A.; Zimmermann, A.; Boyle, F. Journal: Breast Issue: Volume 56(2021)Supplement 1 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 342 A Phase Ib/II study of alpelisib (BYL719) and ganitumab (AMG 479) in adult patients with selected advanced solid tumors. (September 2015) Authors: Juric, D.; Rodón, J.; Bauer, T.M.; Wainberg, Z.; Tolaney, S.; Modi, S.; Martín, A. González; Hengelage, T.; Melendez, M.; Choudhury, S.; Nauwelaerts, H.; Bedard, P.L. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S68 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Matching adjusted indirect comparison of PFS & OS comparing ribociclib + letrozole vs palbociclib + letrozole as first-line treatment of HR+/HER2− ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2. (November 2022) Authors: Jhaveri, K.; O'Shaughnessy, J.; Fasching, P.; Cardoso, F.; Tolaney, S.; Hamilton, E.; Sharma, V.K.; Biswas, C.; Haftchenary, S.; Pathak, P.; Rugo, H. Journal: European journal of cancer Issue: Volume 175(2022)Supplement 1 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. SL 1 The future of innovation: Why arewe conducting clinical trials in countries that are unlikely to be able to afford innovative drugs?. (April 2023) Authors: Tolaney, S. Journal: Breast Issue: Volume 68(2023)Supplement Page Start: S3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. AZD8186 study 1: Phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate. (December 2016) Authors: Lillian, S.; De Bono, J.; Higano, C.; Shapiro, G.; Brugger, W.; Mitchell, P.; Colebrook, S.; Klinowska, T.; Barry, S.; Dean, E.; Martin-Mills, J.; Wisinski, K.; Moorthy, G.; Mills, J.; Cruzalegui, F.; Tolaney, S.; Lang, J.; Jose De Miquel Luken, M.; Kunar, R.; Chatta, G. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes. (April 2023) Authors: Johnston, S.; Toi, M.; O'Shaughnessy, J.; Rastogi, P.; Campone, M.; Neven, P.; Huang, C.S.; Huober, J.; Jaliffe, G. Garnica; Cicin, I.; Tolaney, S.; Goetz, M.P.; Rugo, H.; Senkus, E.; Testa, L.; Del Mastro, L.; Shimizu, C.; Wei, R.; Shahir, A.; Munoz, M. Journal: Breast Issue: Volume 68(2023) Page Start: S22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗